Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review

Emanuela Teveroni, Rossella Lucà, Marsha Pellegrino, Germana Ciolli, Alfredo Pontecorvi, Fabiola Moretti*

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

9 Citazioni (Scopus)

Abstract

Introduction: Restoration of the p53 tumor suppressor function is an attractive anticancer strategy. Despite the development of several therapeutics targeting the two main p53 negative regulators, MDM2 and MDM4, no one has yet reached clinical application. In the past, several efforts have been employed to develop more specific and efficient compounds that can improve and/or overcome some of the features related to small molecule compounds (SMC). Peptides and peptidomimetics are emerging as attractive molecules given their increased selectivity, reduced toxicity and reduced tendency to develop tumor-resistance compared to SMC. Areacovered: This article reviews publications and patents (publicly available up to April 2016) for peptides and derivatives aimed to reactivate the oncosuppressive function of p53, with a particular focus on inhibitors of MDM2/MDM4. Emphasis is placed on the efficacy of these compounds compared to the p53-reactivating small molecules developed so far. Expertopinion: A number of promising peptides for p53 reactivation in cancer therapy have been developed. These compounds appear to possess improved features compared to SMC, especially for their ability to simultaneously target the MDM2/MDM4 inhibitors, and their increased specificity.
Lingua originaleEnglish
pagine (da-a)1417-1429
Numero di pagine13
RivistaExpert Opinion on Therapeutic Patents
Volume26
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Drug Discovery3003 Pharmaceutical Science
  • MDM2
  • MDM4
  • MDMX
  • Pharmacology
  • anticancer peptide
  • dual-inhibitor
  • p53 reactivation therapy
  • therapy-resistance

Fingerprint

Entra nei temi di ricerca di 'Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review'. Insieme formano una fingerprint unica.

Cita questo